Claims
- 1. A compound selected from the group of 2,9-dioxatricyclo [4,3,1,0.sup.3,7 ] decanes of formula I ##STR124## wherein R.sub.1, and R.sub.1" together with the nitrogen atom to which they are bound form a cyclic amino group selected from the group consisting of indolinyl and groups of the formula ##STR125## wherein A represents oxygen or a group >N-A' wherein A' represents an alkyl group containing 1 to 4 carbon atoms which is unsubstituted or substituted in .omega.-position by a substituent which is selected from the group consisting of hydroxy, acyloxy, carbamyloxy, pyridyl, or a phenyl or benzhydryl group, the phenyl rings of which are unsubstituted or substituted by halogen;
- one of R.sub.2 and R.sub.3 is hydrogen and the other represents hydroxy, an acyloxy group Z--COO-- wherein Z is alkyl or alkenyl, containing 1 to 4 carbon atoms, or phenyl, or a carbamyloxy group Z--NHCOO-- wherein Z is alkyl or alkenyl, containing 1 to 4 carbon atoms or phenyl, or R.sub.2 and R.sub.3 jointly represent oxygen;
- one of R.sub.4 and R.sub.5 is hydrogen and the other represents an alkoxy group containing 1 to 6 carbon atoms, or an aralkyloxy group containing 7 to 9 carbon atoms;
- and y and y' each represent hydrogen or jointly form a bond;
- and pharmaceutically acceptable acid addition salts thereof.
- 2. The compound as defined in claim 1 having the formula (I d) ##STR126##
- 3. The compound as defined in claim 1 having the formula (I e) ##STR127## wherein R.sub.11 represents an alkyl group containing 1 to 4 carbon atoms which is unsubstituted or is substituted in its w-position by hydroxy, acyloxy or carbamyloxy, phenyl, pyridyl or halobenzhydryl.
- 4. The compound as defined in claim 1 having the formula (I f) ##STR128##
- 5. The compound as defined in claim 1 which is ##STR129## 3-morpholinomethyl-4.beta.-hydroxy-8-methoxy-10-methyl-2,9-dioxatricyclo [4,3,1,0.sup.3,7 ] decane of the formula (V), and its pharmacologically acceptable acid addition salts.
- 6. A pharmaceutical composition comprising an inert carrier material and a sedatively or saporifically effective amount of a compound as defined in claim 1.
- 7. A method for sedating larger mammals comprising the step of administering to a larger mammal the pharmaceutical composition as defined in claim 6.
- 8. A method for increasing and improving sleep in larger mammals comprising the step of administering to a larger mammal the pharmaceutical composition as defined in claim 6.
- 9. A method of sedating or increasing and improving sleep in larger mammals comprising the step of administering to a larger mammal 0.075 to 1 mg/kg of a compound as defined by claim 1.
- 10. The method of treatment as defined by claim 9, wherein the administering step comprises administering a daily dosage of from about 5 to 50 mg of said compound.
Priority Claims (1)
Number |
Date |
Country |
Kind |
P2607106 |
Feb 1976 |
DEX |
|
Parent Case Info
This is a divisional of Application Ser. No. 904,742 filed May 11, 1978, which is a divisional of Application Ser. No. 770,055 filed Feb. 18, 1977 now U.S. Pat. No. 4,163,055.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3812154 |
Thies |
May 1974 |
|
Divisions (2)
|
Number |
Date |
Country |
Parent |
904742 |
May 1978 |
|
Parent |
770055 |
Feb 1977 |
|